OBJECTIVES: To determine the safety and effectiveness of single-dose rifalazil, a new rifamycin, for the treatment of nongonococcal urethritis (NGU). STUDY DESIGN: Randomized, double-blind trial comparing rifalazil, 2.5, 12.5 or 25 mg, with 1.0 g azithromycin for the treatment of NGU. One hundred and seventy men were evaluated for Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma genitalium infection before therapy and 2- and 5-weeks posttreatment. RESULTS:C. trachomatis, M. genitalium, and U. urealyticum were present in 42%, 24%, and 28% of subjects, respectively. Microbiologic eradication of C. trachomatis with rifalazil 25 mg at 2- and 5- weeks was 85% and 83%, respectively. Rifalazil was ineffective in eradicating M. genitalium and U. urealyticum. Overall clinical cure rates at 2- and 5-weeks were 86% (95% CI 67-96) and 59% (39-78) in the rifalazil-treated 25 mg group, and 77% (56-91) and 63% (41-81) in the azithromycin-treated group. CONCLUSIONS:Rifalazil was well tolerated and eradicates C. trachomatis but not M. genitalium and U. ureaplasma in men with NGU.
RCT Entities:
OBJECTIVES: To determine the safety and effectiveness of single-dose rifalazil, a new rifamycin, for the treatment of nongonococcal urethritis (NGU). STUDY DESIGN: Randomized, double-blind trial comparing rifalazil, 2.5, 12.5 or 25 mg, with 1.0 g azithromycin for the treatment of NGU. One hundred and seventy men were evaluated for Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma genitalium infection before therapy and 2- and 5-weeks posttreatment. RESULTS:C. trachomatis, M. genitalium, and U. urealyticum were present in 42%, 24%, and 28% of subjects, respectively. Microbiologic eradication of C. trachomatis with rifalazil 25 mg at 2- and 5- weeks was 85% and 83%, respectively. Rifalazil was ineffective in eradicating M. genitalium and U. urealyticum. Overall clinical cure rates at 2- and 5-weeks were 86% (95% CI 67-96) and 59% (39-78) in the rifalazil-treated 25 mg group, and 77% (56-91) and 63% (41-81) in the azithromycin-treated group. CONCLUSIONS:Rifalazil was well tolerated and eradicates C. trachomatis but not M. genitalium and U. ureaplasma in men with NGU.
Authors: William M Geisler; Maria Luz G Pascual; Judy Mathew; William D Koltun; Franklin Morgan; Byron E Batteiger; Annette Mayes; Sijia Tao; Selwyn J Hurwitz; Chalom Sayada; Raymond F Schinazi Journal: Antimicrob Agents Chemother Date: 2014-05-05 Impact factor: 5.191
Authors: Evelyn Toh; Xiang Gao; James A Williams; Teresa A Batteiger; Lisa A Coss; Michelle LaPradd; Jie Ren; William M Geisler; Yue Xing; Qunfeng Dong; David E Nelson; Stephen J Jordan Journal: Sex Transm Dis Date: 2022-01-01 Impact factor: 2.830
Authors: Patricia J Kissinger; Kathleen Reilly; Stephanie N Taylor; Jami S Leichliter; Susan Rosenthal; David H Martin Journal: Sex Transm Dis Date: 2009-08 Impact factor: 2.830
Authors: Andrej Trampuz; Christopher K Murphy; David M Rothstein; Andreas F Widmer; Regine Landmann; Werner Zimmerli Journal: Antimicrob Agents Chemother Date: 2007-05-14 Impact factor: 5.191
Authors: Jessica Krahn; Aaron Louette; Vera Caine; Shalane Ha; Tom Wong; Tim T Y Lau; Ameeta E Singh Journal: BMJ Open Date: 2018-12-04 Impact factor: 2.692
Authors: Nicole H T M Dukers-Muijrers; Arjen G C L Speksnijder; Servaas A Morré; Petra F G Wolffs; Marianne A B van der Sande; Antoinette A T P Brink; Ingrid V F van den Broek; Marita I L S Werner; Christian J P A Hoebe Journal: PLoS One Date: 2013-11-20 Impact factor: 3.240